Research programme: cancer therapeutics - Sprint Biosciences/Unknown company

Drug Profile

Research programme: cancer therapeutics - Sprint Biosciences/Unknown company

Alternative Names: PIP4K2a inhibitors

Latest Information Update: 11 Jul 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Sprint Bioscience
  • Developer Unknown
  • Class Antineoplastics
  • Mechanism of Action 1-phosphatidylinositol 4-kinase modulators; Tumour protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Cancer

Most Recent Events

  • 07 Jul 2016 Phosphatidylinositol-5-phosphate 4-kinase type-2 alpha inhibitors licensed to an undisclosed US based company worldwide
  • 07 Jul 2016 Preclinical trials in Cancer in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top